Publications & Presentations


Some of our recent publications:

  1. Ainsworth C. Building a better lymphoma vaccine. Nature Outlook: Lymphoma 563, S52-S54 (2018). doi: 10.1038/d41586-018-07366-1 
  2. Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection.  J Clin Virol 2018;102:84-92.
  3. Grimm JM, Schmeling DO, Dunmire SK, Knight JA, Mullan BD, Ed JA, Brundage RC, Hogquist KA, Balfour HH Jr. Prospective studies of infectious mononucleosis in university students. Clinical & Translational Immunology (2016) 5, e94; doi:10.1038/cti.2016.48. Published online 12 August 2016. 

  4. Balfour HH Jr, Hogquist KA, Verghese P. Epstein-Barr virus and cytomegalovirus. In: Detrick B, Schmitz JL, Hamilton RG, eds. Manual of Molecular and Clinical Laboratory Immunology, eighth edition, ASM Press 2016.DOI 10.1128/9781555818722.

  5. Balfour HH Jr. Epstein-Barr virus vaccine. In: Plotkin SA, Orenstein W, Offit PA, Edwards KM eds. Vaccines, 7th edition. Elsevier 2016.

  6. Johnson KH, Webb C-H, Schmeling DO, Brundage RC and Balfour HH Jr. Epstein–Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clinical & Translational Immunology 2016. DOI:10.1038/cti.2016.28. Published online 13 May 2016

  7. Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 2013; 207:80-8. PMCID:PMC3523797

  8. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus (EBV) infection among children in the United States and factors affecting its acquisition. J Infect Dis 2013;208:1286-93. DOI 10.1093/infdis/jit321

  9. Condon LM, Cederberg LE, Rabinovitch MD, Liebo R, Go JC, Delaney, AS, Schmeling DO, Thomas W, Balfour HH Jr. Age-Specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment. Clin Infect Dis 2014;59:511-8. DOI 10.1093/cid/ciu342

  10. Verghese PS, Schmeling DO, Knight JA, Matas AJ, Balfour HH Jr. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study. Transplantation 2015; 99:602-8. DOI 10.1097/TP.0000000000000354

News Stories

ABC 5: U of M Doctor Working on Mono Vaccine, Hopes It Can Do More

Kare 11: U of M Researchers Developing Vaccine to Prevent Mono, MS

USA Today: Could Childhood Kissing Disease be the Root of your Mystery Illness?


Invited Lectures

  1. April 8, 2013. 39th European Group for Blood & Bone Marrow Transplantation meeting, London, England: "What Bugs to Monitor: EBV?"

  2. February 6, 2013. Pediatric Grand Rounds, University of Minnesota: Epstein-Barr Virus and Infectious Mononucleosis: What Students Can Teach Us."

  3. July 30-31, 2012. Attended an NCI Burkitt Lymphoma Workshop, Philadelphia PA and gave a talk: "Prophylactic Vaccine (gp350) for EBV."

  4. Feb 15, 2012. Laboratory Medicine and Pathology Grand Rounds (with Kris Hogquist), University of Minnesota: "Mono: A Disease for All Seasons."


Recorded Presentation


"Epstein-Barr Virus Infections: Pay Me Now Or Pay Me Later" is available to watch on demand. 

Sign up and watch now

  1. Grimm-Geris J, Dunmire S, Duval L, Filtz E, Leuschen H, Schmeling D, Kulasingam S, Balfour HH Jr. Development of an oral swab method for non-invasive detection of Epstein-Barr virus antibody. Presented at the National Foundation for Infectious Diseases 2018 Annual Conference on Vaccinology Research, Bethesda, MD, April 23-25, 2018.
  2. Grimm JM, Schmeling DO, Cayatte C, Hayes GM, Balfour HH Jr. Rapid Epstein-Barr virus (EBV) antibody (Ab) responses correlate with reduced severity of primary EBV infection. Presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 19, 2015.

  3. Cederberg LE, Rabinovitch MD, Grimm JM, Schmeling DO, Filtz EA, Condon LM, Balfour HH Jr. Prevalence of Epstein-Barr virus (EBV) oral shedding among parents of young children differs significantly by race/ethnicity. Presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 19, 2015.

  4. Reed RC, Schmeling DO, Balfour HH Jr. Cytomegalovirus infection masquerading as necrotizing enterocolitis and ischemic colitis. Presented at the spring meeting of the Society for Pediatric Pathology, Boston, MA, March 21, 2015.

  5. Dunmire SK, Odumade OA, Porter JL, Reyes-Genere J, Baechler EC, Balfour HH Jr, Hogquist KA. Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes. Presented at the EBV 50th Anniversary Meeting. Oxford, UK, March 24, 2014.

  6. Chandolias N, Gillingham KJ, Balfour HH Jr, Matas AJ. Impact of donor and recipient pretransplant EBV antibody status on PTLD incidence in adult kidney transplant recipients. Presented at the American Transplant Congress, Seattle, May 21, 2013.

  7. Balfour HH Jr. Which bugs should we monitor: EBV? Presented at the 39th annual meeting of the European Group for Blood and Marrow Transplantation. London, UK, April 8, 2013.

  8. Wang Y, Stanford SM, Zhou W, Auger JL, Cheng G, Shoyama FM, Balfour HH Jr, Chan AC, Binstadt BA, Bottini N, Peterson EJ. Rheumatoid arthritis-associated PTPN22 promotes Toll-like receptor-driven upregulation of type 1 interferon and innate immunoregulation. Presented at the annual meeting of the American College of Rheumatology, November 13, 2012, Washington, DC.

  9. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr Virus (EBV) antibody (Ab) in US children: Results from the National Health and Nutrition Examination Surveys (NHANES) 2003-2010. Presented at the 52st Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 11, 2012. Abstract V1242a. In: ICAAC 2012 Final Program, pp222-3.

  10. Condon LM, Rabinovitch MD, Cederberg LE, Liebo RV, Delaney AS, Balfour HH Jr. Age-specific Epstein-Barr virus (EBV) antibody (Ab) prevalence and risk factors for early acquisition of infection. Presented at the 52st Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 11, 2012.

  11. Bu W, Schmeling DO, Burbelo PD, Radecki P, Balfour HH Jr, Cohen JI. Neutralizing antibody titers increase over many months to years after Epstein-Barr virus infectious mononucleosis. Presented at the International Congress on Oncogenic Herpesviruses and Associated Diseases, Philadelphia, PA, August 2, 2012.

  12. Verghese P, Ed J, Mullan B, Knight J, Balfour HH Jr. Prospective study of Epstein-Barr virus (EBV), cytomegalovirus (CMV) and BK virus (BKV) infections in solid organ donors and recipients. Presented at the American Transplant Congress, Boston, MA, June 5, 2012.

  13. Balfour HH Jr, Hogquist KA, Holman CJ, Schmeling DO, Mullan BD, Ed JA, Odumade OA, Thomas W, Vezina HE. A prospective study of primary Epstein-Barr virus infection. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 18, 2011. Abstract V494.

Updated: 7/3/2018

Impact of EBV

280,000 cases of mono in U.S college freshmen annually

200,000 new cases of EBV-associated cancers annually worldwide

2.3 million cases of multiple sclerosis worldwide

Donate to The Mono Project

Supported in part by generous grants from the HRK Foundation, the RM Schulze Family Foundation, the Matt Cwiertny Memorial Foundation and the Randy Shaver Cancer Research and Community Fund.